Equities research analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
GLMD stock opened at $3.98 on Wednesday. The firm has a 50 day moving average price of $4.68 and a 200-day moving average price of $4.37. Galmed Pharmaceuticals has a 52-week low of $2.73 and a 52-week high of $23.80. The firm has a market capitalization of $20.08 million, a price-to-earnings ratio of -1.66 and a beta of 0.73.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Best Aerospace Stocks Investing
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What are earnings reports?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Industrial Products Stocks Investing
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
